Translate this page into: Select Language Chinese-simp Chinese-trad Dutch French German Greek Italian Japanese Korean Portuguese Russian Spanish

 Site Search:

Other information

Shire's website for patients and physicians
Website provides information relative to velaglucerase alfa for patients and physicians and provides updates on treatment sites as they become available. To assist patients who wish to begin the treatment protocol, Shire has provided a grant to help patients with expenses related to treatment with velaglucerase.

Website:
www.gaucherpatients.com

Shire HGT, a business unit of global specialty biopharmaceutical company
Shire plc, is committed to collaborating with academic researchers, health care professionals, and patient associations around the world.

Our shared goal is a deeper understanding of life-altering genetic disorders. Our work together includes the investigation and development of therapeutic approaches in rare genetic diseases.

For more information about Shire, visit our corporate web site at:
www.shire.com

OnePathSM will serve as an initial point of contact for physicians interested in the protocol
OnePathSM will be directing inquiries to appropriate clinical trial management personnel.

If you are a physician and are interested in finding out more information, please contact our OnePathsm services at 1-866-888-0660.

For more information, visit our corporate web site at:
www.onepath.com

BraveCommunity.com
BraveCommunity.com is an online resource for patients, families, and health care professionals seeking more information about certain rare diseases and living with rare diseases. The Web site is developed and maintained by Shire Human Genetic Therapies (HGT), a business unit of Shire plc.

Brave Community is a dynamic source of information and insights about certain rare diseases including;

Gaucher Disease
Hunter Syndrome
Fabry Disease
and others